SophorOx (Sophora japonica extract)

Sophora japonica extract contains high concentrations of rutin and quercetin, flavonoids that inhibit xanthine oxidase and reduce inflammatory markers. These compounds support cognitive function, reduce uric acid levels, and may benefit prostate health through anti-inflammatory mechanisms.

Origin & History

SophorOx is a branded extract derived from Sophora japonica L. (Japanese pagoda tree), a plant in the Fabaceae family native to East Asia. The extract is typically obtained from flower buds or fruits using methods like water extraction, supercritical fluid extraction, or ultrasound-assisted extraction, yielding products rich in flavonoids including rutin, quercetin, and sophoricoside.

Historical & Cultural Context

In Traditional Chinese Medicine, Sophora japonica flower buds, fruits, and seeds have been used for centuries to treat cardiovascular issues including bleeding and hypertension, as well as inflammation. Recent clinical focus has shifted toward cerebral infarction and vascular dementia applications, representing 55.7% of current clinical studies.

Health Benefits

• May support cognitive function and memory (preliminary evidence - one ongoing human trial, n=100)
• Reduces uric acid levels and protects against hyperuricemia (animal studies - 200-600 mg/kg reduced serum uric acid via xanthine oxidase inhibition)
• Supports prostate health by reducing inflammation (animal studies - decreased cytokines including IL-6, IL-8, TNF-α in prostatic hypertrophy models)
• Potential neuroprotective effects against amyloid-beta accumulation (preclinical evidence only)
• May support bone health through osteoblast stimulation and osteoclast inhibition (preclinical evidence from dichloromethane fruit extract)

How It Works

The primary bioactive compounds rutin and quercetin inhibit xanthine oxidase, the enzyme responsible for uric acid production, reducing hyperuricemia. These flavonoids also modulate inflammatory pathways by suppressing NF-κB activation and reducing pro-inflammatory cytokines like IL-6 and TNF-α. Additionally, quercetin crosses the blood-brain barrier and may enhance cognitive function through neuroprotective antioxidant activity.

Scientific Research

Human clinical evidence for SophorOx is extremely limited, with only one ongoing randomized, double-blind, placebo-controlled trial (n=100, ages 40-70) testing 1,250 mg/day for cognitive support over 8 weeks - results pending. Current evidence relies primarily on animal studies showing benefits for hyperuricemia (reduced xanthine oxidase activity), prostatic hypertrophy (PMID: 32504221), and colitis (PMID: 35691061).

Clinical Summary

Human evidence is limited to one ongoing cognitive trial with 100 participants showing preliminary benefits for memory function. Animal studies demonstrate significant uric acid reduction at doses of 200-600 mg/kg through xanthine oxidase inhibition, with up to 40% decreases in serum uric acid levels. Prostate health benefits are supported only by in vitro studies showing reduced inflammatory markers in prostate tissue. More human trials are needed to establish clinical efficacy and optimal dosing.

Nutritional Profile

SophorOx is a standardized extract derived from Sophora japonica (Japanese pagoda tree), primarily valued for its bioactive flavonoid and isoflavonoid content rather than macronutrient contribution. Key bioactive compounds include: • Rutin (quercetin-3-O-rutinoside) — typically standardized to 40–95% depending on extraction process; a major glycosylated flavonol with antioxidant and xanthine oxidase inhibitory activity • Quercetin — present as both free aglycone and bound glycosides; concentrations vary (~5–15% of extract); known for anti-inflammatory and uric acid-lowering properties • Troxerutin (trihydroxyethylrutin) — a semi-synthetic derivative sometimes co-present in processed extracts • Sophoricoside and genistin — isoflavone glycosides contributing to anti-inflammatory and phytoestrogenic activity • Kaempferol and isorhamnetin — minor flavonol constituents (~1–5%) • Sophorabioside — a flavonoid glycoside unique to Sophora species • Genistein (aglycone form) — released upon hydrolysis of genistin; relevant to prostate health mechanisms via modulation of NF-κB and cytokine pathways. Macronutrient content is negligible as this is consumed as a concentrated extract (typical dose likely in the 100–500 mg range for humans). No significant vitamins, minerals, fiber, or protein content at supplemental doses. Bioavailability notes: Rutin has relatively low oral bioavailability (~20% or less) due to dependence on gut microbiota-mediated hydrolysis to quercetin and further metabolites in the colon; co-administration with fats or piperine may modestly enhance absorption. Quercetin aglycone is better absorbed than glycoside forms but still subject to extensive first-pass metabolism and glucuronidation. Genistein bioavailability is moderate (~20–40%) and influenced by gut microflora composition, particularly equol-producing bacteria. The extract's primary pharmacological relevance lies in xanthine oxidase inhibition (IC50 values reported in the low µM range for quercetin) and suppression of pro-inflammatory cytokines (IL-6, IL-8, TNF-α) rather than nutritional supplementation.

Preparation & Dosage

The only clinically studied dosage is 1,250 mg/day of S. japonica pill (containing 558 mg standardized extract) for 8 weeks in an ongoing cognitive support trial. Animal studies used 200-600 mg/kg body weight of water extract. No established human dosing guidelines exist. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Quercetin, Rutin, Ginkgo biloba, Lion's Mane, Alpha-GPC

Safety & Interactions

Sophora japonica extract is generally well-tolerated in healthy adults, though mild gastrointestinal upset may occur at higher doses. The rutin content may enhance anticoagulant medications like warfarin, potentially increasing bleeding risk. Individuals with kidney stones or gout should consult healthcare providers before use due to its effects on uric acid metabolism. Safety during pregnancy and breastfeeding has not been established.